← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT05519683

Home Transcutaneous Electrical Acustimulation (TEA)

Trial Parameters

Condition Irritable Bowel Syndrome With Constipation
Sponsor University of Michigan
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 160
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-11-02
Completion 2026-09
Interventions
TEALexapro

Brief Summary

This study will assess the efficacy of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.

Eligibility Criteria

Inclusion Criteria: * Those with ongoing and symptomatic Irritable Bowel Syndrome with Constipation (IBS-C) * Significant mean worst abdominal pain severity (as defined by the study protocol, which will be shared with results reporting) on a Visual Analog Scale (VAS) pain score during the Phase-in period * Symptoms present at least 1 day/week in the last 3 months with symptom onset at least 6 months prior to the diagnosis. * Abdominal pain is not adequately relieved at the time of screening and the time of randomization. Exclusion Criteria: * Unrelated active disorder which may involve abdominal pain, such as inflammatory bowel disease, diabetes or unstable thyroid disease. * Pregnancy, plans to become pregnant, or lactation. Any potential patient of child-bearing potential will complete a pregnancy test at Visit 1 and if the test is positive that individual will be excluded from future participation. * Any other condition, which in the opinion of the investigator would impede complian

Related Trials